Conditions: Hepatitis C
Keywords: Hepatitis C Virus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 605
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients

Detailed description:
Allocation: Randomized Stratified

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Daclatasvir intervention 2: Telaprevir intervention 3: Peginterferon alfa-2a intervention 4: Ribavirin
Intervention descriptions: intervention 1: Film-coated tablet, oral, 60 mg, once daily, 24 weeks intervention 2: Film-coated tablet, oral, 750 mg, 3 times daily intervention 3: Solution for injection, subcutaneous injection, 180 μg, weekly intervention 4: Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day

Protocol document: